FR3074683B1 - Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide - Google Patents

Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide Download PDF

Info

Publication number
FR3074683B1
FR3074683B1 FR1761809A FR1761809A FR3074683B1 FR 3074683 B1 FR3074683 B1 FR 3074683B1 FR 1761809 A FR1761809 A FR 1761809A FR 1761809 A FR1761809 A FR 1761809A FR 3074683 B1 FR3074683 B1 FR 3074683B1
Authority
FR
France
Prior art keywords
compositions
polyaminoacid
human glucagon
injection solution
aqueous injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1761809A
Other languages
English (en)
Other versions
FR3074683A1 (fr
Inventor
You-Ping Chan
Alexandre GEISSLER
Romain Noel
Richard Charvet
Nicolas LAURENT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1761809A priority Critical patent/FR3074683B1/fr
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to MA051018A priority patent/MA51018A/fr
Priority to SG11202005320VA priority patent/SG11202005320VA/en
Priority to EP18826205.9A priority patent/EP3720471B1/fr
Priority to CN201880088457.9A priority patent/CN111670042A/zh
Priority to US16/213,836 priority patent/US11191812B2/en
Priority to BR112020011484-7A priority patent/BR112020011484A2/pt
Priority to PCT/EP2018/084065 priority patent/WO2019110837A1/fr
Priority to JP2020530963A priority patent/JP2021505597A/ja
Priority to CA3084700A priority patent/CA3084700A1/fr
Priority to KR1020207019243A priority patent/KR20200107951A/ko
Priority to MA051017A priority patent/MA51017A/fr
Priority to MX2020005915A priority patent/MX2020005915A/es
Priority to AU2018380993A priority patent/AU2018380993A1/en
Publication of FR3074683A1 publication Critical patent/FR3074683A1/fr
Publication of FR3074683B1 publication Critical patent/FR3074683B1/fr
Application granted granted Critical
Priority to PH12020550828A priority patent/PH12020550828A1/en
Priority to IL275184A priority patent/IL275184A/en
Priority to SA520412140A priority patent/SA520412140B1/ar
Priority to US17/404,547 priority patent/US20210386830A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

[0001] L'invention concerne ainsi des compositions stables physiquement sous forme d'une solution aqueuse injectable, dont le pH est compris entre 6,0 et 8,0, comprenant au moins : a) du glucagon humain et b) un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes Hy, [0002] Dans un mode de réalisation, les compositions selon l'invention comprennent en outre une hormone gastrointestinale.
FR1761809A 2017-12-07 2017-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide Active FR3074683B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR1761809A FR3074683B1 (fr) 2017-12-07 2017-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
MX2020005915A MX2020005915A (es) 2017-12-07 2018-12-07 Composiciones en forma de una solución acuosa inyectable que comprende glucagón humano y un copoliaminoácido.
SG11202005320VA SG11202005320VA (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
CN201880088457.9A CN111670042A (zh) 2017-12-07 2018-12-07 包含人胰高血糖素和共聚氨基酸的可注射水溶液形式的组合物
US16/213,836 US11191812B2 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
BR112020011484-7A BR112020011484A2 (pt) 2017-12-07 2018-12-07 composições na forma de uma solução aquática injetável compreendendo glucagon humano e um co-poliaminoácido
PCT/EP2018/084065 WO2019110837A1 (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
JP2020530963A JP2021505597A (ja) 2017-12-07 2018-12-07 ヒトグルカゴンおよびコポリアミノ酸を含む注射水溶液の形態の組成物
AU2018380993A AU2018380993A1 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
KR1020207019243A KR20200107951A (ko) 2017-12-07 2018-12-07 인간 글루카곤 및 코-폴리아미노산을 포함하는 주사용 수용액 형태의 조성물
MA051018A MA51018A (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
EP18826205.9A EP3720471B1 (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
CA3084700A CA3084700A1 (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
MA051017A MA51017A (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
PH12020550828A PH12020550828A1 (en) 2017-12-07 2020-06-04 Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
IL275184A IL275184A (en) 2017-12-07 2020-06-07 Preparations in the form of an aqueous solution for injection that include human glucagon and copolyamino acid
SA520412140A SA520412140B1 (ar) 2017-12-07 2020-06-07 تركيبات في صورة محلول مائي قابل للحقن يشتمل على جلوكاجون بشري وحمض بولي أمينو مشترك
US17/404,547 US20210386830A1 (en) 2017-12-07 2021-08-17 Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1761809 2017-12-07
FR1761809A FR3074683B1 (fr) 2017-12-07 2017-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide

Publications (2)

Publication Number Publication Date
FR3074683A1 FR3074683A1 (fr) 2019-06-14
FR3074683B1 true FR3074683B1 (fr) 2020-01-10

Family

ID=62091961

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1761809A Active FR3074683B1 (fr) 2017-12-07 2017-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide

Country Status (1)

Country Link
FR (1) FR3074683B1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1202607A (en) * 1968-01-10 1970-08-19 Novo Terapeutisk Labor As Improvements in or relating to stable glucagon solutions and their preparation
CN104114155B (zh) * 2012-01-09 2019-02-15 阿道恰公司 Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液

Also Published As

Publication number Publication date
FR3074683A1 (fr) 2019-06-14

Similar Documents

Publication Publication Date Title
SG11201810939PA (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
PH12018502558A1 (en) Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
FR3001896B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
FR3001895B1 (fr) Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
NZ705178A (en) Anti-prolactin receptor antibody formulations
PH12020550828A1 (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
PH12020550827A1 (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
WO2019110797A8 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
EA201591176A1 (ru) Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
MX2014011459A (es) Proteinas nutritivas cargadas y metodos.
CY1112353T1 (el) Παραγωγα μεταστινης και χρηση αυτων
MA49678A (fr) Compositions sous forme d'une solution aqueuse injectable comprenant au moins l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
MX2017006594A (es) Proteinas y congujados proteinicos con efecto hidrofobo aumentado.
PH12020550804A1 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
BR112012032215A2 (pt) composição farmacêutica líquida compreendendo imunoglobulinas g humanas (iggs) e composição sólida
FR3074683B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
AR090244A1 (es) Formulacion de anticuerpo anti-selectina p
FR3061660B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3043557B1 (fr) Composition a action rapide d'insuline comprenant un citrate substitue
FR3074681B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3074422B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3072875B1 (fr) Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3079414B1 (fr) Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20190614

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7